Role of the CTLA-4 receptor in T cell activation and immunity

Immunologic Research

Volumn 18, Issue 2, 1998, Pages 103-115

  Scheipers, Peter ^a   Reiser, Hans ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Anergy; Apoptosis; B7; Costimulation; CTLA 4

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA B7 ANTIGEN; LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; CELL CYCLE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0031730773     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02788753     Document Type: Review

References (93)

1. Dariavach P, Mattel MG, Golstein P, Lefranc MP: Human Ig superfamily CTLA-4 gene: Chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18:1901-1905.
2. Harper K, Balzano C, Rouvier E, Mattel MG, Luciani MF, Golstein P: CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991;147:1037-1044.
3. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
4. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793-801.
5. Parsons KR, Young JR, Collins BA, Howard CJ: Cattle CTLA-4. CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28. Immunogenetics 1996;43:388-391.
6. Metzler WJ, Bajorath J, Fenderson W, Shaw SY, Constantine KL, Naemura J, et al.: Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Biol 1997;4:527-531.
7. Bajorath J, Metzler WJ, Linsley PS: Molecular modeling of CD28 and three-dimensional analysis of residue conservation in the CD28/ CD 152 family. J Mol Graph Model 1997;15:135-139.
8. Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naemura J, et al.: Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994;180:2049-2058.
9. Fargeas CA, Truneh A, Reddy M, Hurle M, Sweet R, Sekaly RP: Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4. J Exp Med 1995;182:667-675.
10. Morton PA, Fu XT, Stewart JA, Giacoletto KS, White SL, Leysath CE, Evans RJ, et al.: Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). J Immunol 1996; 156:1047-1054.
11. Ellis JH, Burden MN, Vinogradov DV, Linge C, Crowe JS: Interactions of CD80 and CD86 with CD28 and CTLA4. J Immunol 1996;156: 2700-2709.
12. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, et al.: Regulation of CTLA-4 expression during T cell activation. J Immunol 1996; 156:4154-4159.
13. Alegre ML, Noel PJ, Eisfelder BJ, Chuang E, Clark MR, Reiner SL, et al.: Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996; 157:4762-4770.
14. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, et al.: CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992;149: 3795-3801.
15. Alegre ML, Schiels H, Thompson CB, Gajewski TF: Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998; 3347-3356.
16. Castan J, Tenner-Racz K, Racz P, Fleischer B, Broker BM: Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues. Immunology 1997;90:265-271.
17. Kuiper HM, Brouwer M, Linsley PS, van Lier RA: Activated T cells can induce high levels of CTLA-4 expression on B cells. J Immunol 1995;155:1776-1783.
18. Vandenborre K, Delabie J, Boogaerts MA, De Vos R, Lorre K, De Wolf-Peeters C, et al.: Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease. Am J Pathol 1998;152:963-973.
19. Vyth-Dreese FA, Dellemijn TA, Majoor D, de Jong D: Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. Eur J Immunol 1995;25:3023-3029.
20. Finn PW, He H, Wang Y, Wang Z, Guan G, Listman J, et al.: Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. J Immunol 1997;158:4074-4081.
21. Leung HT, Bradshaw J, Cleaveland JS, Linsley PS: Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86. contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 1995;270:25,107-25,114.
22. Shiratori T, Miyatake S, Ohno H, Nakaseko C, Isono K, Bonifacino JS, et al.: Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 1997;6:583-589.
23. Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB: Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. J Immunol 1997;159:144-151.
24. Bradshaw JD, Lu P, Leytze G, Rodgers J, Schieven GL, Bennett KL, et al.: Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation. Biochemistry 1997;36:15975-15982.
25. Zhang Y, Allison JP: Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci USA 1997;94: 9273-9278.
26. Waterhouse P, Marengere LE, Mittrucker HW, MakTW: CTLA-4, a negative regulator of T-lymphocyte activation. Immunol Rev 1996;153:183-207.
27. Stephens DJ, Banting G: Insulin dependent tyrosine phosphorylation of the tyrosine internalisation motif of TGN38 creates a specific SH2 domain binding site. FEBS Lett 1997;416:27-29.
28. Liu Y: Is CTLA-4 a negative regulator for T cell activation? Immunol Today 1997;18:569-572.
29. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al.: CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
30. Calvo CR, Amsen D, Kruisbeek AM: Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor ζ and ZAP70. J Exp Med 1997;186:1645-1653.
31. + T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci USA 1998;95:10,083-10,088.
32. Krummel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-2540.
33. 3 Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-2550.
34. Hamel ME, Noteboom E, Kruisbeek AM: Non-responsiveness of antigen-experienced CD4 T cells reflects more stringent co-stimulatory requirements. Immunology 1998; 93:366-375.
35. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al.: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-988.
36. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
37. + T cells. Immunity 1997;7:885-895.
38. Wagner DH, Jr., Hagman J, Linsley PS, Hodsdon W, Freed JH, Newell MK: Rescue of thymocytes from glucocorticoid-induced cell death mediated by CD28/CTLA-4 cost-mulatory interactions with B7-1/B7-2. J Exp Med 1996;184:1631-1638.
39. Waterhouse P, Bachmann MF, Penninger JM, Ohashi PS, Mak TW: Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice. Eur J Immunol 1997;27: 1887-1892.
40. Chambers CA, Cado D, Truong T, Allison JP: Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 1997;94:9296-9301.
41. Romagnani S: Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225-235.
42. Reiser H, Stadecker MJ: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335:1369-1377.
43. Thompson CB: Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995;81:979-982.
44. Walunas TL, Bluestone JA: CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol 1998; 160:3855-3860.
45. Le Gros G, Kirman J, Camberis M, McCoy K: CTLA-4 blockade enhances both Th1 and Th2 immune responses. Keystone Symposia, Keystone, CO, 1998, p 125.
46. Fallarino F, Fields PE, Gajewski TF: B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med 1998;188:205-210.
47. L induction. J Immunol 1998; 160:12-15.
48. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, et al.: CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A 1995;92:811-815.
49. Van Parijs L, Abbas AK: Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science 1998;280: 243-248.
50. Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, et al.: The role of CTLA-4 in the regulation and initiation of T cell responses. Immunol Rev 1996;153:27-46.
51. Schwartz RH: Models of T cell anergy: Is there a common molecular mechanism? J Exp Med 1996;184:1-8.
52. Sloan-Lancaster J, Evavold BD, Allen PM: Induction of T cell anergy by altered T cell-receptor ligand on live antigen-presenting cells. Nature 1993;363: 156-159.
53. + T cells induces anergy and apoptosis. J Immunol 1998;160: 3655-3665.
54. + T cells. J Exp Med 1996;184:19-29.
55. Cone RE, Cochrane R, Lingenheld EG, Clark RB: Elevation of intracellular cyclic AMP induces an anergic-like state in Th1 clones. Cell Immunol 1996;173:246-251.
56. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6: 411-417.
57. Vidard L, Colarusso LJ, Benacerraf B: Specific T cell tolerance may be preceded by a primary response. Proc Natl Acad Sci USA 1994; 91:5627-5631.
58. Van Parijs L, Biuckians A, Abbas AK: Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 1998;160:2065-2071.
59. + T cells in vitro. Int Immunol 1997; 9:935-944.
60. Mollereau B, Decken M, Deas O, Rieux-Laucat F, Hirsch F, Bernard A, et al.: CD2-induced apoptosis in activated human peripheral T cells: A Fas-independent pathway that requires early protein tyrosine phosphorylation. J Immunol 1996; 156:3184-3190.
61. Park CS, Yashiro Y, Tai XG, Toyooka K, Hamaoka T, Yagita H, et al.: Differential involvement of a Fas-CPP32-like protease pathway in apoptosis of TCR/CD9-costimulated, naive T cells and TCR-restimulated, activated T cells. J Immunol 1998;160:5790-5796.
62. Woodle ES, Smith DM, Bluestone JA, Kirkman WM, 3rd, Green DR, Skowronski EW: Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J Immunol 1997; 158:2156-2164.
63. Sambhara SR, Miller RG: Programmed cell death of T cells signaled by the T cell receptor and the a3 domain of class I MHC. Science 1991;252:1424-1427.
64. Bachmann MF, Waterhouse P, Speiser DE, McKall-Faienza K, Mak TW, Ohashi PS: Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells. J Immunol 1998;160:95-100.
65. Miyatake S, Nakaseko C, Umemori H, Yamamoto T, Saito T: Src family tyrosine kinases associate with and phosphorylate CTLA-4 (CD152). Biochem Biophys Res Commun 1998;249:444-448.
66. Schneider H, Prasad KV, Shoelson SE, Rudd CE: CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med 1995;181:351-355.
67. Marengère LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, MakTW: Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996;272: 1170-1173.
68. Su X, Zhou T, Wang Z, Yang P, Jope RS, Mountz JD: Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 1995;2:353-362.
69. Pani G, Fischer KD, Mlinaric Rascan I, Siminovitch KA: Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase. J Exp Med 1996;184:839-852.
70. Burshtyn DN, Scharenberg AM, Wagtman N, Rajagopalan S, Berrada K, Yi T, et al.: Recruitment of tyrosine phosphatase HCP by the killer cell inhibitory receptor. Immunity 1996;4:77-85.
71. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, et al.: Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by FcgRIIB1. Science 1995;268:293-297.
72. Chambers CA, Allison JP: The role of tyrosine phosphorylation and PTP-IC in CTLA-4 signal transduction. Eur J Immunol 1996;26:3224-3229.
73. + T cells. Science 1996;271:1272-1276.
74. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM: Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science 1997; 278:124-128.
75. Maier CC, Greene MI: Biochemical features of anergic T cells. Immunol Res 1998;17:133-140.
76. + T cells express perturbed AP-1 and NF-κB transcription factors. Proc Natl Acad Sci USA 1996;93:979-984.
77. Baichwal VR, Baeuerle PA: Activate NF-κB or die? Curr Biol 1997;7:R94-96.
78. Lai JH, Tan TH: CD28 signaling causes a sustained down-regulation of IκBα which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994; 269:30,077-30,080.
79. Harhaj EW, Maggirwar SB, Good L, Sun SC: CD28 mediates a potent costimulatory signal for rapid degradation of IκBβ which is associated with accelerated activation of various NF-κB/Rel heterodimers. Mol Cell Biol 1996; 16:6736-6743.
80. Ravi R, Bedi A, Fuchs EJ: CD95 (Fas)-induced caspase-mediated proteolysis of NF-κB. Cancer Res 1998;58:882-886.
81. Pioli C, Gatta L, Goso C, Francesconi A, Frasca D, Doria G: CTLA4 negatively regulates cytokine production by NFκB modulation. Keystone Symposia, Keystone, CO, 1998, p 82.
82. Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, et al.: Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998;94:339-352.
83. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kägi D, et al.: Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998;12:806-819.
84. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, et al.: Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998;9:267-276.
85. Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML: Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 1998; 188:199-204.
86. Ochi A, Kaga S, Berg K: Positive and negative signallings of T cell activation. Keystone Symposia, Keystone, CO, 1998, p 59.
87. DeBenedette MA, Shahinian A, Mak TW, Watts TH: Costimulation of CD28 T lymphocytes by 4-1BB ligand. J Immunol 1997; 158:551-559.
88. Saoulli K, Lee SY, Cannons JL, Yeh WC, Santana A, Goldstein MD, et al.: CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998;187:1849-1862.
89. Saito K, Sakurai J, Ohata J, Kohsaka T, Hashimoto H, Okumura K, et al.: Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol 1998;160:4225-4231.
90. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al.: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
91. Thompson CB, Allison JP: The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-450.
92. Fukumoto T, Torigoe N, Kawabata S, Murakami M, Uede T, Nishi T, et al.: Peptide mimics of the CTLA4-binding domain stimulate T cell proliferation. Nat Biotechnol 1998;16:267-270.
93. Cepero E, Hnatyszyn HJ, Kraus G, Lichtenheld MG: Potent inhibition of CTLA-4 expression by an anti CTLA-4 ribozyme. Biochem Biophys Res Commun 1998; 247:838-843.